These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33243967)

  • 1. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.
    Hu L; Kong Z; Meng Q; Wang J; Zhou M; Yu J; Jiang X
    Med Sci Monit; 2020 Nov; 26():e927221. PubMed ID: 33243967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
    Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
    Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of induction chemotherapy for non-operable esophageal squamous cell carcinoma followed by concurrent chemoradiotherapy: a single-centre experience.
    Xiang G; Chai G; Lyu B; Li Z; Yin Y; Wang B; Pan Y; Shi M; Zhao L
    Radiol Oncol; 2024 Sep; 58(3):444-457. PubMed ID: 39287163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
    Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
    Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.
    Zhou XL; Zhu WG; Zhu ZJ; Wang WW; Deng X; Tao WJ; Ji FZ; Tong YS
    Oncologist; 2019 Aug; 24(8):e677-e686. PubMed ID: 31040254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.
    Chen Y; Guo L; Cheng X; Wang J; Zhang Y; Wang Y; Ke S; Shi W
    Radiother Oncol; 2018 Oct; 129(1):154-160. PubMed ID: 29122362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
    Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
    Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
    Chen CY; Li CC; Chien CR
    World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Huang JQ; Liang HW; Liu Y; Chen L; Pei S; Yu BB; Pan XB
    Front Immunol; 2024; 15():1355198. PubMed ID: 38550598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
    Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
    Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy.
    Chen YH; Lu HI; Chien CY; Lo CM; Wang YM; Chou SY; Su YY; Shih LH; Li SH
    Sci Rep; 2017 Jan; 7():41785. PubMed ID: 28134308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma.
    Liu G; Wang Y; Wang C; He Y; E M
    Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1423-1430. PubMed ID: 33115264
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
    JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers.
    Chen F; Luo H; Xing L; Liang N; Xie J; Zhang J
    Thorac Cancer; 2018 Jan; 9(1):59-65. PubMed ID: 29024498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
    Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
    Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma.
    Ochi M; Murakami Y; Nishibuchi I; Kubo K; Imano N; Takeuchi Y; Kimura T; Hamai Y; Emi M; Okada M; Nagata Y
    J Radiat Res; 2021 Jan; 62(1):142-148. PubMed ID: 33392619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.